- Datametrex (DM) announced that its wholly-owned telehealth company, Medi-Call, has signed a partnership agreement with Lucira Health
- The agreement, signed on December 22, 2022, will allow Medi-Call to provide telehealth services to Lucira clients
- Medi-Call is a subscription-based software-as-a-service mobile application that connects patients with physicians in real-time
- Datametrex is a technology-focused company with a prominent footprint in artificial intelligence and machine learning
- Datametrex AI (DM) is holding steady, trading at $0.07 per share
Datametrex’s (DM) Medi-Call subsidiary has signed a partnership agreement with Lucira Health.
The agreement, signed on December 22, 2022, will allow Medi-Call to provide telehealth services to Lucira clients.
Lucira is making headway in the next generation of diagnostic testing and is a leader in at-home diagnostics. It has created a Health Canada-approved at-home diagnostic testing device for detecting both COVID-19 and the flu, influenza A and B.
Lucira has combined the most accurate COVID-19 test with the only commercially available at-home flu test. Within 30 minutes or less, users will know whether they have COVID-19 or the flu.
Lucira will direct patients to Medi-Call’s telehealth services through the Lucira app and website. This will expose Medi-Call to more potential patients.
Once results are in, if Lucira users are positive for any viruses, their platform will redirect users to Medi-Call’s telehealth services to see a physician or get a prescription.
Medi-Call is a subscription-based software-as-a-service mobile application that connects patients with physicians in real-time.
Datametrex is a technology-focused company with a prominent footprint in artificial intelligence and machine learning. Through the power of artificial intelligence, Datametrex creates solutions for cyber security, telehealth and electric vehicles.
Datametrex AI (DM) is holding steady, trading at $0.07 per share at 1:02 pm ET.
